News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Welcomes Landmark "Victory for Patient" in Intellectual Property Case



4/30/2013 10:44:53 AM

LONDON, 30 April 2013 - Teva UK Limited (Teva) has welcomed the judgment of the Court of Appeal today in support of its case against AstraZeneca relating to the validity of the patent covering quetiapine ER (a generic version of Seroquel®). This ruling confirmed the decision of the UK High Court in March 2012 that AstraZeneca’s patent was invalid.

Seroquel®, an antipsychotic treatment, was launched in its generic form quetiapine by Teva on expiry of the patent covering the molecule in 2012. Teva also launched an Extended Release formulation of quetiapine, which AstraZeneca deemed to be covered by their patent covering the extended release formulation.

In today’s ruling, Lord Justice Mummery, supported by two other Lord Justices of the Court of Appeal, agreed with Teva that AstraZeneca’s patent covering the Extended Release version of Seroquel using a gelling agent to regulate the release rate, was not inventive and would therefore not warrant additional patent protection, on top of the patent covering the molecule itself. When giving the ruling, the Court stated “[The High Court judge’s] conclusion was justified on a proper application of his correct understanding of the relevant principles of patent law to the facts found by him on the evidence.” The judges refused AstraZeneca leave to appeal to a higher court.

Teva UK Limited Managing Director Richard Daniell welcomed the outcome: “Delivering the best medicines at the best price for the benefit of patients is our number one priority. Whilst we are wholly committed to respecting valid intellectual property rights, we will fight for our patients where necessary to ensure they have access to sustainable, high-quality and affordable healthcare products.

“We see the conclusion of this appeal as a victory for us, our patients, but also the pharmacist who works on the patient’s behalf and for sustainable healthcare.”

The case was brought by Teva to facilitate an early launch of its generic versions of Seroquel® XL on the day that the patent for quetiapine expired in the UK in March last year. In March 2012 the High Court agreed with Teva that the patent was invalid. AstraZeneca sought to overturn this decision, but the appeal ruling today resulted in victory for Teva.

Richard Daniell said that the case had raised important industry issues: “Our pharmacists know that Teva supports them, and stands up for them. We hope this case sends a signal that we are working with our customers, with the interests of the patient always coming first.”

In addition to this victory, Teva says that it will make an application to claim its legal costs from AstraZeneca.

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email media.enquiries@tevauk.com.

About Teva UK Limited

Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

PRFilter

PRFilter is a relevance engine that filters press releases for users based on a personal profile of their interests created from their own, or their publication's, published articles. The public website also provides anyone with the ability to search thousands of releases from multiple sources or view the most relevant releases in particular areas of interest.

Releases marked with [PRFilter] in the subject line of RealWire release emails indicate PRFilter determined the release passed an individuals relevance threshold. Users can login and increase or decrease this threshold. Users can also train PRFilter to determine release relevance more accurately by providing feedback – “More”, this release is relevant or “Less”, this release is not relevant.

Please visit PRFilter to log in or contact RealWire for more information.

News Receiver Options

Receivers members area – the receivers members area allows you to amend your news category options and preferences, and access your own personal RSS feed of relevant news. Log in now or request log in details.

Unsubscribe – should you wish to unsubscribe from RealWire’s distribution, please click here. We would very much value your feedback on why you wish to be removed in order for us to continue to improve and develop our service.

Disclaimer:

Whilst RealWire Limited endeavour to ensure the accuracy of the information contained in this Release, RealWire Limited cannot accept any liability for:-

• the inaccuracy or otherwise of any information contained in this Release; or

• any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release; or

• any loss or suffering which may be caused by or to any party either as a result of the information contained in this Release or such information contained in this Release being inaccurate or otherwise misleading.

In the event that any information contained in this Release is inaccurate or misleading then please contact RealWire.

RealWire’s privacy policy is available on our website.

RealWire:

The registered address of RealWire is:

Realwire Limited, Unit 1, Exchange Close, North Hykeham, Lincoln, LN6 3TR.

Realwire Limited is a company registered in England and Wales: 4026690


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES